Biocept Stock

Biocept FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of Biocept (BIOC) as of Sep 5, 2026 is 43.93 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -75.00 % — a change of -158.57% (higher).

FCF Conversion

43.93 %

YoY

-158.57%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Biocept is 2026 43.93 % . FCF Conversion Rate (FCF/EBITDA) of Biocept was 2025 -75.00 % . It decreases by -158.57% higher compared to the previous year.

The Biocept FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2015
90.39 USD
Jan 1, 2016
87.93 USD
Jan 1, 2017
97.40 USD
Jan 1, 2018
91.57 USD
Jan 1, 2019
96.63 USD
Jan 1, 2020
121.19 USD
Jan 1, 2021
-75.00 USD
Jan 1, 2022
43.93 USD
The Biocept FCF Conversion history
YEARFCF ConversionYoY
43.93 %-158.57%
-75.00 %-161.89%
121.19 %+25.42%
96.63 %+5.52%
91.57 %-5.98%
97.40 %+10.76%
87.93 %-2.71%
90.39 %-4.40%
94.54 %
Access this data via the Eulerpool API

Biocept Stock analysis

What does Biocept do? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocept stock

FCF Conversion Rate (FCF/EBITDA) of Biocept is 43.93 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Biocept changed from -75.00 % to 43.93 %, representing a -158.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Biocept since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Biocept with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Biocept

All Key Metrics — Biocept